摘要
目的探索多药耐药相关蛋白(MRP)在非小细胞肺癌(NSCLC)的表达,以及与病理类型、病期及预后的关系。方法以原位杂交法检测冰冻NSCLC组织。结果全组58例NSCLC、MRPmRNA总表达率为74.1%,鳞癌为72.0%,腺癌为73.3%。MRP的表达与病理类型、TNM分期及分化程度无关。47例接受化疗的NSCLC中,35例MRP表达(+~++)者生存率明显低于MRP表达(-)者(P<0.05),中位生存期分别为8.7个月和21个月(P<0.05);12例MRP表达(+~++)鳞癌生存率亦明显低于7例MRP表达(-)者(P<0.05),中位生存期分别为6个月和19.5个月(P<0.05)。
Objective To investigate expression of multidrug resistance associated protein (MRP) in non small cell lung cancer and its relation to histological type, TNM staging and prognosis. Methods In situ hybridization was used to examine mRNA expression of MRP. Results The overall positive rate of MRP expression was 74.1%, with 73.3% and 72.0% in adenocarcinoma and squamous cell carcinoma, respectively. The expression of MRP was not related to histological subtypes, TNM staging and cell differentiation. In 47 patients who received chemotherapy, 35 patients with positive MRP expression(+~++) showed worse prognosis than in those with negative expression ( P <0.05). The median survival time was 8.7 months and 21 months in patients with positive and negative MRP expession, respectively. In patients with squamous cell carcinoma, the survival rate was significantly lower in patients ( n =12) with positive MRP expression than in those ( n =7) with negative MRP expression ( P <0.05). Their median survival time was 6 months and 19.5 months, respectively ( P < 0.05). Conclusion The expression of MRP gene is negatively correlated with survival of patients with squamous cell carcinoma, but not adenocarcinoma, who received chemotherapy.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1999年第2期112-113,共2页
Chinese Journal of Oncology
基金
国家"九五"攻关项目
关键词
肺肿瘤
多药耐药性
药物疗法
非小细胞肺癌
Lung neoplasms Carcinoma, non small cell lung Multidrug resistance In situ hybridization